/
Haoxi Health Technology Ltd. is a holding company that provides digital marketing solutions in China, with a client base concentrated in the healthcare and medical aesthetics industries. The company focuses on online short video and social-media-based advertising, offering integrated services that span campaign planning, creative content production, media placement, and ongoing data-driven optimization. Haoxi Health Technology distributes advertisements through major Chinese platforms such as Douyin, Toutiao, WeChat, and Sina Weibo via media partners, aiming to help advertisers acquire, convert, and retain consumers across these channels. Its role in the market is centered on connecting healthcare-related advertisers with targeted digital audiences, leveraging performance-oriented marketing techniques and closed-loop campaign management. Founded in 2018 and headquartered in Beijing, China, Haoxi Health Technology operates within the communication services sector, specifically the advertising and online marketing segment, serving as a specialized intermediary between healthcare brands and the country’s large and highly engaged mobile internet user base.
$0.22
$0.00 (-1.79%)
EOD Jul 17, 2026
Operating margin is thin at 3.54%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 71.9%, still solid.
ROIC dropped from 66.68% to 17.17%, capital efficiency is deteriorating. Negative free cash flow of -$803K. The business is consuming cash, not generating it.
0.0x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$49M
▲ +71.9% YoY
Net Income (TTM)
$1M
▲ +33.2% YoY
Op. Margin
3.54%
▼ -0.7pp YoY
ROIC
17.17%
▼ -49.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$803K
▲ +12.5% YoY
Op. Cash Flow (TTM)
$1M
▲ +16.1% YoY
Net Debt
-$5M
Net Cash Position
Cash & Equiv.
$7M
3Y CAGR: +55.7%
Continue Research
At a P/E of 0.0, Haoxi Health Technology (HAO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Haoxi Health Technology scores 64/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Haoxi Health Technology scores 64 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 3.5% operating margin and a 17.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh HAO's valuation and scores 64/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.